PF-Atlas › Clinical Trials › NCT00391443

BUILD 3: Bosentan Use in Interstitial Lung Disease

Bosentan · Phase 3

Registry ID
NCT00391443
Phase
Phase 3
Status
Completed
Drug / intervention
Bosentan
Sponsor
Actelion
Start
2007-02
Enrollment
616

About this trial

BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.

View NCT00391443 on ClinicalTrials.gov →

Explore related

All Bosentan trialsAll IPF trials

Related trials

Bosentan — NCT00318175Bosentan — NCT00070590bosentan — NCT00625469bosentan — NCT01518595Bosentan — NCT00631475bosentan — NCT00071461
Medical disclaimer. This page summarizes public trial data for NCT00391443 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.